| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
This trial is included in the following systematic reviews and meta-analyses:
atrial fibrillation
-
antithrombotics
-
secondary prevention of thromboembolic events
Related trials
RE-LY 110mg subgroup, 2010 - dabigatran 100mg vs warfarin
FFAACS , 2001 - aspirin vs placebo (on top fluidione)
SIFA, 1997 - Indobufen vs warfarin
EAFT, 1993 - aspirin vs placebo
See also:
RE-LY 150mg subgroup study, |
|
Treatments
| Studied treatment |
dabigatran 150mg daily
|
| Control treatment |
warfarin
|
Patients
| Patients | patients with a prior stroke or transient ischemic attack |
Method and design
| Randomized effectives | NA / NA (studied vs. control) |
| Design | Parallel groups |
| Blinding | open |
| Follow-up duration | 2 y |
| Remarks | sub group ( 20% of the overall study population in RE-LY) |
Results
n/N
n/N
thrombo-embolic event (cerebral or systemic)
TE event or ischemic stroke or systemic embolism
Haemmorhagic stroke
intracranial hemorrhage
| Relative risks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Endpoint | Events (%) | Relative Risk | 95% CI | Endpoint definition in the trial |
Ref | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studied treat. | Control treat. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The primary endpoint (if exists) appears in blod characters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference(s) used for data extraction: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Absolute risk reduction | ||||
| Endpoint | Events rate | Absolute risk reduction (ARR) |
||
|---|---|---|---|---|
| Studied treat. | Control treat. | |||
Reference(s)
| Trials register # | NA |
-
1.Diener HC, Connolly S, Ezekowitz MD, et al..
Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY.
American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 195
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2010 TrialResults-center - All Rights Reserved
Tweet this
notify a friend